Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation (VCEL) pioneers patient-specific cellular therapies for sports medicine and severe burn care through advanced regenerative science. This dedicated news hub provides investors and medical professionals with timely updates on the company’s progress in transforming treatment paradigms.
Access authoritative information on FDA approvals, clinical trial outcomes, and strategic initiatives shaping the future of cell-based therapies. Our curated collection includes:
- Quarterly earnings reports and financial disclosures
- Product launch announcements and manufacturing updates
- Research collaborations and intellectual property developments
- Regulatory milestones for novel treatment platforms
Bookmark this page for streamlined tracking of Vericel’s advancements in autologous cell therapies, including innovations in cartilage repair and burn wound management. Stay informed about developments that impact both patient care and investment considerations in the evolving biologics sector.
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care markets, has announced it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. The company's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss financial results and business highlights.
Investors can access the live webcast on Vericel's Investor Relations website. Participants are advised to register at least 15 minutes before the scheduled start time. For those joining by telephone, registration is required to receive dial-in details and a personal passcode. Presentation slides will be available on the webcast and Investor Relations section. A replay of the webcast will be accessible on Vericel's website until August 1, 2025.
Vericel (NASDAQ: VCEL), a prominent player in sports medicine and severe burn care, announced its participation in the Truist Securities MedTech Conference. The event will feature a fireside chat with President and CEO Nick Colangelo, along with CFO Joe Mara, scheduled for 2:30 p.m. ET on June 18, 2024. Investors and interested parties can access the webcast through Vericel's Investor Relations website.
Vericel (NASDAQ:VCEL), a key player in advanced therapies for sports medicine and severe burn care, announced its participation in the Leerink Partners Healthcare Crossroads Conference. The event will take place on May 29, 2024, at 9:40 a.m. ET. Vericel's President and CEO, Nick Colangelo, along with CFO Joe Mara, will represent the company in a fireside chat. Investors and interested parties can access the webcast of the presentation through the Investor Relations section of the Vericel website.
Vericel (NASDAQ:VCEL) reported a 25% increase in total revenue to $51.3 million in the first quarter of 2024. The company achieved record revenue for MACI of $40.2 million and saw a 63% growth in Burn Care revenue. Adjusted EBITDA grew by 325%. The full-year 2024 revenue guidance was raised to $238-$242 million. Vericel had a strong start to the year with significant margin expansion and profitability growth, positioning the company well for continued growth. The company also reported positive progress in new product launches and market penetration.
FAQ
What is the current stock price of Vericel (VCEL)?
What is the market cap of Vericel (VCEL)?
